| 前收市價 | 18.86 |
| 開市 | 18.75 |
| 買盤 | 19.20 x 100 |
| 賣出價 | 19.22 x 100 |
| 今日波幅 | 18.61 - 19.35 |
| 52 週波幅 | 18.61 - 30.52 |
| 成交量 | |
| 平均成交量 | 640,146 |
| 市值 | 1.441B |
| Beta 值 (5 年，每月) | 1.64 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -1.02 |
| 業績公佈日 | 2024年5月02日 - 2024年5月06日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 30.83 |
Insider MonkeyWhat Makes Veracyte (VCYT) a Lucrative Investment?
Next Century Growth Investors, LLC, an investment Management Company, released its “Micro-Cap Strategy” fourth-quarter investor letter. A copy of the letter can be downloaded here. The recent surge in the stock market highlights the significance of current macroeconomic indicators and the Fed’s outlook on future interest rates. The strategy returned 9.54% (net of fees) compared to […]
InvestorPlace7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet. To mitigate the downside risks, it may be better to consider undervalued enterprises. Of course, specifically targeting biotech stocks that trade below their intrinsic or perceived value offers no guarantee of success. Still, given the sometimes extreme mobility that the ecosystem facilitates, it may pa
Insider MonkeyVeracyte, Inc. (NASDAQ:VCYT) Q4 2023 Earnings Call Transcript
Veracyte, Inc. (NASDAQ:VCYT) Q4 2023 Earnings Call Transcript February 22, 2024 Veracyte, Inc. misses on earnings expectations. Reported EPS is $-0.39 EPS, expectations were $-0.07. Veracyte, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank you […]
